chufangao/CTO huggingface dataset:
Clinical trial NCT02850536: CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
Official title: Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer
Acronym: HITM-SURE
Sponsor: Roger Williams Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-01
Primary completion date: 2018-12-31
Completion date: 2021-09-17
Clinical trial NCT04038489: COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
Official title: COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Therapy for Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Stage I-III Breast Cancer
Acronym: Breast 51
Sponsor: University of Virginia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-18
Primary completion date: 2023-04-30
Completion date: 2023-04-30
Plan to share individual participant data: NO
Clinical trial NCT04461886: A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
Official title: A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
Sponsor: Nobelpharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 100.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-08
Primary completion date: 2021-12-07
Completion date: 2021-12-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04648020: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.
Official title: A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer
Acronym: VOICE
Sponsor: Monopar Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Interim Analysis did not meet the pre-defined threshold for efficacy of a 15% absolute difference in SOM prevention between Validive and placebo.
Enrollment: 190.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-11
Primary completion date: 2023-05-14
Completion date: 2023-05-14
Clinical trial NCT05583188: Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
Official title: Neoadjuvant Soft Tissue Ablation Utilizing Aliya™ Pulsed Electric Fields With Systemic Therapy in Early-Stage Resectable Non-Small Cell Lung Cancer (NSCLC)
Acronym: VIGOR
Sponsor: Galvanize Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Strategic
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-01
Primary completion date: 2024-02-08
Completion date: 2024-03-18
Plan to share individual participant data: NO
IPD sharing description: No plan of data sharing
Clinical trial NCT04627831: Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography
Official title: Randomized Parallel Group Study Comparing the Renal Safety of CAPTISOL-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in Patients With Impaired Renal Function Undergoing Coronary Angiography
Sponsor: Ligand Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Internal decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2023-03-31
Completion date: 2023-04-30
Clinical trial NCT05091528: A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Official title: An Open-label, Phase 1/2, Dose-escalation and Expansion Study of SBT6050 Combined With Other HER2-directed Therapies in Subjects With Pretreated Unresectable Locally Advanced and/or Metastatic HER2-expressing or HER2-amplified Cancers
Sponsor: Silverback Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision based on strategic re-alignment
Enrollment: 2.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-02-08
Primary completion date: 2022-07-07
Completion date: 2022-07-07
Baseline population: All enrolled participants who received at least one dose of SBT6050.
Limitations and caveats: Early termination leading to small numbers of participants analyzed.
Plan to share individual participant data: NO
Clinical trial NCT04524403: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)
Sponsor: Corcept Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 150.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-09
Primary completion date: 2022-07-29
Completion date: 2022-08-25
Baseline population: All enrolled patients
Plan to share individual participant data: NO
Clinical trial NCT02420223: Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients
Official title: Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant (HCT) Recipients
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-17
Primary completion date: 2018-07-31
Completion date: 2020-02-29
Plan to share individual participant data: NO
Clinical trial NCT03685149: Pilot Randomized Trial With Flecainide in ARVC Patients
Official title: Pilot Randomized Trial With Flecainide in ARVC Patients
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-23
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: NO
IPD sharing description: This is a small pilot trial with limited dataset which will be mostly explored by enrolling center investigators.
Clinical trial NCT06006286: A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Official title: A Pilot Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: 0 participants registered
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-08-08
Primary completion date: 2023-11-10
Completion date: 2023-11-10
Clinical trial NCT03929835: Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa
Official title: A Phase Ⅱ, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa
Sponsor: TO Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: withdrawn due to COVID-19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-01
Primary completion date: 2022-09-01
Completion date: 2022-09-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03801525: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
Official title: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Acronym: ULTRA-V
Sponsor: TG Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Strategic/Business decision
Enrollment: 277.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-05-16
Primary completion date: 2022-12-20
Completion date: 2022-12-20
Baseline population: Safety population consisted of all participants who received at least one dose of any study drug (ublituximab, umbralisib, and venetoclax).
Limitations and caveats: Due to sponsor's business decision, the clinical trial was terminated by the sponsor prematurely. As such, the study results are reflective of the data captured to the time of study termination and with limited data verification.
Plan to share individual participant data: NO
Clinical trial NCT03827018: KPL-301 for Subjects With Giant Cell Arteritis
Official title: A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis
Sponsor: Kiniksa Pharmaceuticals International, plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 70.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-20
Primary completion date: 2020-08-13
Completion date: 2020-11-25
Plan to share individual participant data: NO
Clinical trial NCT03298893: Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months
Official title: A Phase-I Study of Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months. NiCOL
Acronym: NiCOL
Sponsor: Institut Curie (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-27
Primary completion date: 2020-10-30
Completion date: 2022-03-07
Plan to share individual participant data: YES
IPD sharing description: Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.
IPD time frame: Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.
IPD access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).
Clinical trial NCT02474173: Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Official title: Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Drug supply issues
Enrollment: 31.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-01-15
Primary completion date: 2022-10-26
Completion date: 2022-10-26
Clinical trial NCT04482699: RAPA-501-Allo Therapy of COVID-19-ARDS
Official title: Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS
Sponsor: Rapa Therapeutics LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Change in eligible patient population
Enrollment: 1.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-12-30
Primary completion date: 2021-09-13
Completion date: 2021-09-13
Plan to share individual participant data: NO
Clinical trial NCT04561076: Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
Official title: A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
Sponsor: Hengenix Biotech Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor strategy
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-12-09
Primary completion date: 2021-09-06
Completion date: 2021-09-18
Plan to share individual participant data: NO
Clinical trial NCT06034899: A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants
Official title: A Phase 1, 2-part, Open-label, Randomized, 2-period, 2-sequence, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-986196 Phase 2 Tablet Formulation at Two Dose Levels in Healthy Adult Participants
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business objectives have changed.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-09-22
Primary completion date: 2023-11-30
Completion date: 2023-11-30
Plan to share individual participant data: NO
IPD sharing description: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Clinical trial NCT04531878: BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases
Official title: Jian-She Wang of Children's Hospital of Fudan University
Sponsor: Children's Hospital of Fudan University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-08
Primary completion date: 2023-02-08
Completion date: 2023-02-08
Plan to share individual participant data: NO
Clinical trial NCT02090998: Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines
Official title: A Comparison of the Efficacy of 5% Lidocaine Anesthetic to Provide SPGB Vs. Elavil for the Treatment of Transformed Migraine
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: no patients during covid pandemic
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-05-31
Primary completion date: 2020-03-16
Completion date: 2020-03-16
Clinical trial NCT04702048: Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye
Official title: The Evaluation of Retinal PhotoReceptors And Vasculature in Moderate and Severe Non-proliferative Diabetic Retinopathy Patients After Intravitreal Aflibercept on Using Adaptive Optics Imaging Study (PRAVA) Study
Acronym: PRAVA
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: sponsor withdrew funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-01
Primary completion date: 2024-02-01
Completion date: 2024-02-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03493568: Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)
Official title: Open Label, Randomized (1:1) Clinical Trial to Evaluate Switching From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE Study).
Acronym: Be-OnE
Sponsor: IRCCS San Raffaele (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The futility analysis on 24-week results estimated that there was only 2% probability of verifying the study hypothesis of a higher proportion pat. with no residual viremia through 48w in arm E/C/F/TAF
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-02-06
Primary completion date: 2018-03-20
Completion date: 2020-07-31
Plan to share individual participant data: YES
IPD sharing description: Data shared in Scientific Congress (abstract and pubblications)
Clinical trial NCT04385095: Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
Official title: A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection
Sponsor: Synairgen Research Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 221.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-16
Primary completion date: 2021-02-17
Completion date: 2021-11-16
Plan to share individual participant data: NO
IPD sharing description: No plan to share data
Clinical trial NCT03750656: Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation
Official title: Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation
Acronym: HyTa Stent
Sponsor: University of Kansas Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Not accruing patients quickly enough
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-12
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Plan to share individual participant data: NO
Clinical trial NCT04274023: Study on TSR-042 in Advanced Clear Cell Sarcoma
Official title: Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
Acronym: ACCeSs
Sponsor: Italian Sarcoma Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulty of enrollment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-01-29
Primary completion date: 2024-01-29
Completion date: 2024-01-29
Plan to share individual participant data: NO
Clinical trial NCT04034355: Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
Official title: A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in the Adjuvant Treatment of Patients With Stage III or High-risk Stage II Colorectal Cancer
Acronym: POLAR-A
Sponsor: Egetis Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: On 01 March 2020, the Sponsor decided to place recruitment and dosing of patients on hold following interactions with the French regulatory authority, ANSM and the US clinical hold of another study (POLAR-M).
Enrollment: 301.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-07
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Baseline population: Safety analysis set consisting of all randomized patients who received at least one dose of IMP. Patients were analyzed according to the study treatment they actually received.
Plan to share individual participant data: NO
Clinical trial NCT02706392: Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Official title: Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated due to slow accruals.
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-03-16
Primary completion date: 2021-05-17
Completion date: 2021-09-28
Plan to share individual participant data: NO
Clinical trial NCT04378868: Role of Delay and Antibiotics on Perforation Rate While Waiting Appendectomy
Official title: Role of Delay and Antibiotics on PERForation Rate While Waiting appendECTomy - Randomized Non-inferiority Trial
Acronym: PERFECT
Sponsor: Helsinki University Central Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1800.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-05-18
Primary completion date: 2023-01-23
Completion date: 2023-02-23
Plan to share individual participant data: NO
Clinical trial NCT02633397: A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
Official title: A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 130.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-11
Primary completion date: 2022-05-04
Completion date: 2022-05-04
Plan to share individual participant data: NO
Clinical trial NCT04904913: A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
Official title: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 328.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-06-08
Primary completion date: 2023-03-29
Completion date: 2023-12-06
Clinical trial NCT02921256: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Official title: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 363.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-01-11
Primary completion date: 2020-04-21
Completion date: 2023-09-20
Clinical trial NCT03856047: Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Official title: Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 706.0 (ACTUAL)
Number of arms: 12.0
Start date: 2019-03-01
Primary completion date: 2020-03-02
Completion date: 2021-03-25
Baseline population: The full analysis set included all randomised participants according to the intention-to-treat principle.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Clinical trial NCT04016805: Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Official title: A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Sponsor: TG Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Strategic/Business decision
Enrollment: 41.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-08-05
Primary completion date: 2022-05-22
Completion date: 2022-05-22
Limitations and caveats: Due to sponsor's business decision, the clinical trial was terminated by the sponsor prematurely. No analysis was done at the termination of the trial, therefore, outcome, and safety data are not available and the numbers of participants analyzed are reported as 0.
Plan to share individual participant data: YES